Radiation oncologist @MayoRadOnc @MayoClinic | views = my own
Rochester, MN
Joined March 2020
- Tweets151
- Following393
- Followers598
- Likes471
Alexander Sherry retweeted
Excited for the interest in our biomarker work from the urologic oncology community @VincentWenxinXu @PavlosMsaouel @AlexSherryMD @kieko_hara @d_shapiro1 @MDAndersonnews
🏆 Congratulations to @ChadTangMD et al. on receiving our April IMPACT Award!
This month's winning paper stands out for its contribution to understanding how we can better predict outcomes for patients with Oligometastatic Clear-cell Renal Cell Carcinoma — an important step forward for personalised care.
Well deserved. 👏
#IMPACTAward #EuropeanUrology #renalcellcarcinoma #Oncology #Urology
Alexander Sherry retweeted
@GiulioFrancoli1 at #estro2026 presents early results of the randomized PERSIAN trial. Results are early showing excellent PSA response in both arms (mdt slightly better) but definitely more to come.
Alexander Sherry retweeted
New @EurUrol! Pooled trials @PeterMacCC / @UTMDAnderson shows adding Pembrolizumab to MDT for oligometastatic #kidneycancer ⬆️ PFS (28 vs 17 mo; HR 0.57), esp. after prior therapy - shorturl.at/WWvBg - Correlative data confirm MDT+ICI-evoked immune activation #Kcsm #RadOnc
Alexander Sherry retweeted
Excited to review our paper on KIM-1 and ctDNA in oligomet RCC and the K-COMPASS prognostic model published this wk in @EuropeanUrology. Great collaboration between @UTMDAnderson and @DanaFarber. Specifically @VincentWenxinXu and @DrChoueiri
Full paper: authors.elsevier.com/a/1mhMr…
Alexander Sherry retweeted
This is how we finally start harnessing the untapped for decades power of *prognostic* modeling (not “predictive”) for biomarker development. Onwards! 🔬@ChadTangMD @VincentWenxinXu @AlexSherryMD @OncHahn @AmandaNizamMD @KidneyCancer @ebludmir @PGrivasMDPhD
The K-COMPASS study by @ChadTangMD shows how ctDNA and KIM-1 are prognostic and can be used to estimate treatment-free survival in patients with oligometastatic RCC #ASCOGU26 @PavlosMsaouel
Alexander Sherry retweeted
At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.
Alexander Sherry retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6….
The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
Alexander Sherry retweeted
Thanks for @Uromigos for letting me chat about radiation in oligometastatic RCC. @_ShankarSiva @piet_ost @ndesai2005 @KidneyCancer @AlexSherryMD @ebludmir @ASTRO_org @ACKoongMDPhD @MDAndersonNews @VedangMurthy @PavlosMsaouel @salvolarosa
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Chad Tang discusses: Metastasis-directed Therapy in RCC.
Alexander Sherry retweeted
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics
authors.elsevier.com/a/1ljMf…
Alexander Sherry retweeted
1/5 How reproducible are phase III oncology trials?
📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/4062… 👇#MsaouelLab
Alexander Sherry retweeted
👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25
🐺Dr @ChadTangMD presenting Abs15 "World-wide oligometastatic prostate cancer (omPC)meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration"
5⃣ RCTs omPC: MDT+SOC vs. SOC
[STOMP, ORIOLE, ARTO, SABR-COMET, EXTEND]
n = 472 (248 MDT+SOC, 224 SOC,)
median follow-up = 41 mo
- CSPC (58%)
- treated with ADT (74%) +/- ARPI (54%)
- treated primary prostate (82%).
✅PFS 0.45 (0.35-0.58), P<0.0001
✅rPFS 0.59 (0.46-0.76), P<0.0001
✅CRFS 0.58 (0.37-0.91), P=0.020
✅OS 0.64 (0.40-1.01), P=0.057
PFS benefit across subgroups [castration, prior tx, staging, ADT/ARPI] (all HR < 0.52, all P < 0.05)
🩺Clinical implications:
- WOLVERINE demonstrated significant benefit of MDT for rPFS & CRFS (trend OS)
- Several ongoing studies to evaluate the role of MDT 👇
👥@sandysrimd @BrandonMahal @AlexSherryMD @piet_ost @drdavidpalma @EllenKimMD @MutlaySayan @DrPaulNguyen @DrRanaMcKay @Silke_Gillessen @Uromigos @DrChoueiri @neerajaiims @OncBrothers @OncoAlert @ASCO @ASCOPost @PGrivasMDPhD @AtishChoudhury @PrafulRavi1 @xiaoweimd
Alexander Sherry retweeted
Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by @ChadTangMD at #GU25.
Alexander Sherry retweeted
Proud to present the results of the EXTEND breast basket led by #JayReddy from @MDAndersonNews in the @IJROBP . This is a randomized trial of oligometastatic breast cancer patients randomized to +/- MDT. Unfortunately not all trials were positive.
shorturl.at/vhaTy
Alexander Sherry retweeted
Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology: brnw.ch/21wNKGK @AlexSherryMD @ebludmir @PavlosMsaouel @ErikVanZwet
Alexander Sherry retweeted
Panels A1-3 and B1-3 are examples of MRI-based alignment and A4 and B4 show non-contrast CT based alignment. Since this paper we have treated many more IVC thrombi. The MRL represents an ideal fit for this indication.
Alexander Sherry retweeted
Terrific first first-author paper from EJ Beck, with outstanding mentorship by @AlexSherryMD! The evolving SEP landscape… growing #’s of SEPs per trial, suboptimal publication rates for PROs, and more! @michael_overman @ParseghianC @vserpashigbie @MarcusAFlorez @ChadTangMD
Recently published:
Secondary endpoint utilization and publication rate among phase III oncology trials, by Esther J. Beck, Alexander D. Sherry, et al.
bit.ly/3WGRcRU
@AlexSherryMD @JAbiJaoude @fumikochino @PavlosMsaouel @ebludmir @MDAndersonNews #openaccess
Alexander Sherry retweeted
Recently published:
Secondary endpoint utilization and publication rate among phase III oncology trials, by Esther J. Beck, Alexander D. Sherry, et al.
bit.ly/3WGRcRU
@AlexSherryMD @JAbiJaoude @fumikochino @PavlosMsaouel @ebludmir @MDAndersonNews #openaccess
Alexander Sherry retweeted
Pleasure working with @ebludmir and @AlexSherryMD on the pancreatic arm of extend. Full paper here ascopubs.org/doi/10.1200/JCO…. Watch for a tweetorial from @ebludmir soon.
Dr. Ethan Ludmir, along with Dr. Chad Tang, shares why findings from a recent trial suggest a new treatment approach "potentially represents a paradigm shift in treating metastatic pancreatic cancer.” Read more: bit.ly/3WzgSjp @ebludmir @ChadTangMD #PancreaticCancer #EndCancer
